Primobolan 100

Primobolan 100 Dragon Pharma — Overview

Primobolan 100 Dragon Pharma is methenolone enanthate at 100 mg/ml — a DHT-derived injectable anabolic steroid with a long enanthate ester producing a half-life of approximately 10–14 days. Methenolone is one of the few anabolic steroids that was genuinely developed for clinical use and remained on the market for decades; it does not aromatize, carries no progestogenic activity, produces no hepatotoxicity (injectable, non-17α-alkylated), and has a comparatively mild side effect profile relative to its anabolic output. These characteristics make Primobolan one of the most consistently used compounds in lean mass, recomposition, and competition-prep protocols where maintaining quality of gains without estrogenic or hepatic complications is the primary objective.

Injectable Primobolan is substantially more bioavailable than the oral form (methenolone acetate) and requires higher weekly doses to reach equivalent anabolic activity — the effective range for men starts at 400 mg/week and extends to 600–800 mg/week for advanced users. At these doses, Primobolan produces slow, steady, lean muscle accumulation without water retention, making it well suited to longer cycles of 12–16 weeks where gradual tissue accrual compounds over time. Available at Steroid Warehouse in 100 mg/ml vials, Primobolan 100 Dragon Pharma is the entry-point format for methenolone enanthate; the 200 mg/ml version (Primobolan 200) reduces injection volume for users running higher weekly doses.

About the Compound: Methenolone Enanthate

Methenolone is a structurally modified DHT (dihydrotestosterone) derivative. Two key structural features distinguish it from other DHT-derived AAS: a C1–C2 double bond that moderates androgenic potency relative to its anabolic activity, and a 1-methyl group that protects the molecule from hepatic degradation — the same feature that makes the oral acetate form viable without 17α-alkylation. This combination is unusual: most orally active AAS require 17α-alkylation for bioavailability, which comes with hepatotoxicity. Methenolone achieves oral activity through the 1-methyl substitution, and in the injectable enanthate form, this protection is a structural bonus that ensures the compound remains intact through hepatic circulation without generating the toxic metabolites associated with 17α-alkylated compounds.

Methenolone does not aromatize. The DHT backbone lacks the C19 methyl group necessary for aromatase activity, and the structural modifications further preclude estrogen conversion. There is no progestogenic receptor binding either — methenolone is inert at the progesterone receptor. The result is a clean androgenic anabolic environment: the androgen receptor is activated with an anabolic-to-androgenic selectivity that is favorable relative to testosterone (anabolic rating ~88, androgenic rating ~44), producing lean mass accumulation without estrogenic water retention, prolactin elevation, or hepatic stress.

The enanthate ester attached to methenolone produces a half-life of approximately 10–14 days, enabling a twice-weekly injection schedule. At 100 mg/ml, Primobolan 100 Dragon Pharma requires a practical injection volume of 2–4 ml per injection for common doses; users running 600–800 mg/week may prefer Primobolan 200 (200 mg/ml) to halve injection volume.

What Primobolan Does

• Lean, dry muscle accumulation without water retention — the complete absence of aromatization eliminates estrogenic subcutaneous fluid; gains on a Primobolan cycle reflect lean tissue and glycogen without bloat; the resulting mass is denser and more permanent than the gains from aromatizing compounds, as there is no water weight that disappears post-cycle; this quality is central to Primobolan's long-standing use in pre-competition and lean phase protocols
• Muscle preservation during caloric restriction — methenolone's androgen receptor activation maintains a positive nitrogen balance even in a caloric deficit; the anti-catabolic effect is less extreme than trenbolone (which also antagonizes glucocorticoids) but is real and meaningful; users in cutting phases using Primobolan as the anabolic base consistently report superior lean tissue preservation compared to drug-free cutting; this makes it well suited to gradual fat-loss cycles of 12 weeks or more
• Immune function enhancement — methenolone was used clinically in immunodeficiency and wasting conditions; at supraphysiologic doses, it stimulates lymphocyte activity; while not a primary objective in athletic use, this property contributes to improved recovery capacity and resilience during high-volume training phases
• Low side-effect burden relative to anabolic output — the mild androgenic rating (~44 vs testosterone's 100), zero aromatization, absence of progestogenic activity, and no hepatotoxicity create a side effect profile that is more manageable than most comparably anabolic injectable AAS; cardiovascular and androgenic effects are present but attenuated; this is why Primobolan is one of the very few AAS documented as used at low doses in women and in clinical contexts where side effect control is paramount
• Strength increases proportional to lean mass — unlike trenbolone (which produces strength gains disproportionate to tissue accretion via CNS effects), Primobolan strength gains track closely with actual lean mass growth; the result is a strength increase that builds steadily over the cycle without the CNS stimulatory effects that accompany 19-nor compounds; the quality is consistent — no dramatic peaks, no crashes

Who It's For

• Intermediate to advanced users in lean mass, cutting, or competition prep — Primobolan's slow, steady nature and 12–16 week cycle requirement mean it rewards patience; the compound is appropriate for users who have completed at least one testosterone base cycle and understand how their body responds to injectable AAS; first-cycle users may find Primobolan's slow onset less motivating than faster-acting compounds, but the quality of lean tissue produced over time is consistently valued by experienced athletes
• Users who need high anabolic output with minimal hormonal disruption — the specific scenario where Primobolan outperforms most alternatives is a 14–16 week lean phase where the priority is lean mass accumulation or preservation with the fewest possible side effects: no estrogen management headaches, no prolactin monitoring, no hepatic strain, and a manageable androgenic profile; athletes subject to drug testing who require faster clearance should note that methenolone enanthate's long half-life means detection windows extend for several weeks
• What differentiates Primobolan from similar alternatives: compared to Masteron 200 (drostanolone enanthate), Primobolan has a higher anabolic-to-androgenic ratio and is better suited to lean mass accumulation rather than purely cosmetic hardening effects; Masteron is more androgenic and adds density and anti-estrogenic benefit, but contributes less actual anabolic tissue; compared to Anavar 50 (oxandrolone), injectable Primobolan avoids the hepatic load entirely and is appropriate for longer cycle durations; Anavar is more favorable for nitrogen retention per mg and produces less HPTA suppression, but requires liver support on longer runs; compared to Primobolan 200, the 100 mg/ml version offers more granular dose titration at lower weekly totals, while Primobolan 200 is the practical choice at 600–800 mg/week where volume reduction matters
• Users who should choose something else: users looking for rapid mass or dramatic strength gains within 8 weeks should run a more potent compound — Primobolan at 400–600 mg/week over 12–16 weeks will not produce the same short-term impact as a testosterone or nandrolone base cycle; users whose primary goal is maximum anabolic output per dollar spent will find higher-rated AAS more efficient; Primobolan's value is quality and tolerability over time, not speed or magnitude

Primobolan vs Alternatives

Combinations

Side Effects & Management

Bloodwork Monitoring

PCT

The enanthate ester's half-life of ~10–14 days means methenolone clears sufficiently for PCT to begin approximately 2 weeks after the last injection. Primobolan's HPTA suppression is more moderate than trenbolone, nandrolone, or high-dose testosterone, which generally allows a standard 4-week SERM PCT to achieve full recovery. Prolactin and estrogen management during PCT is not a Primobolan-specific concern; focus is on LH/FSH stimulation via SERM.

Practical Summary

References